Abstract Chronic myeloid leukemia (CML) is effectively treated with small molecule BCR::ABL1 tyrosine kinase inhibitors (TKIs) but as in all cancers, early identification of suboptimal responders and non-responders is a challenge.
Johan Richter
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Johan
Contact Johan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack